News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

2 Down But Not Out Biotech Stocks Investors Should Take a Second Look at



11/1/2016 6:03:13 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
This has been an overall rough year for biotech stocks. With the iShares Biotechnology Nasdaq ETF down more than 20% YTD, investors have learned more than ever that betting on biotech is always a risky business. However, as is often the case when the baby is thrown out with the bathwater, this downturn in biotech valuations has created some interesting buying opportunities.

Amid this sea of red tape, I believe investors would be wise to take a second look at beaten-down blue-chip biotech stocks Celgene Corporation and Bristol-Myers Squibb.

Read at Motley Fool


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES